Reports Q2 revenue $8.31B, consensus $7.58B. “Lilly’s financial results in Q2 were led by Mounjaro sales and a strong performance from Growth Products,” said David Ricks, Lilly’s chair and CEO. “Exciting scientific breakthroughs, such as TRAILBLAZER-ALZ 2 in Alzheimer’s disease and SURMOUNT-3 and -4 in obesity, encourage us to continue to make significant investments that support our new medicines including multiple launches expected by the end of 2023 to help more patients around the world.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly (NYSE:LLY) Soars on Q2 Beat & Raise
- Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
- Notable companies reporting before tomorrow’s open
- Nektar sues Eli Lilly for breach of contract, Reuters reports
- Nektar may have path forward in atopic dermatitis, says Mizuho
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue